Annexon, Inc. filed a current report with the SEC on August 6, 2026, disclosing a press release describing clinical responses observed in the first U.S. and European patient cohort of its GBS FORWARD Study evaluating tanruprubart.

Key Highlights

  • Study name: The disclosed press release covers the GBS FORWARD Study, Annexon's clinical investigation of tanruprubart in patients with Guillain-Barre Syndrome.
  • Patient cohort: According to the filing, the first U.S. and European patient cohort was covered in the press release dated August 6, 2026.
  • Clinical response: The press release title states "Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week," as incorporated by reference in the filing.
  • Signatory: Jennifer Lew, Executive Vice President and Chief Financial Officer, signed the filing on behalf of Annexon, Inc.
  • Exchange listing: Annexon's common stock, par value $0.001 per share, trades on The Nasdaq Stock Market under the symbol ANNX.

Annexon's GBS FORWARD Study: Tanruprubart Cohort Data Disclosed

Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company headquartered in Brisbane, California, filed a current report on August 6, 2026, under Item 8.01 (Other Events) to announce the availability of clinical data from its GBS FORWARD Study. The study is evaluating tanruprubart as a treatment for Guillain-Barre Syndrome, a neurological condition. The filing incorporated by reference a press release describing outcomes observed in the first cohort of patients enrolled in the United States and Europe.

According to the filing, the press release title characterizes the findings as reflecting "Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week." The filing notes that the quotes contained within the press release are not incorporated by reference, while the remainder of Exhibit 99.1 is. The current report was signed by Jennifer Lew, Executive Vice President and Chief Financial Officer, on behalf of Annexon, Inc., which is incorporated in Delaware and holds Commission File Number 001-39402.

What Was Disclosed

Annexon filed a current report on August 6, 2026, attaching a press release as Exhibit 99.1 regarding clinical response data from the GBS FORWARD Study's first U.S. and European patient cohort treated with tanruprubart, its investigational complement inhibitor.